In 304 adults with early Parkinson's disease, flexible-dose tavapadon improved MDS-UPDRS II+III score at 26 weeks vs placebo (LSM −10.3 vs −1.2; difference −9.1). Adverse events 76% vs 55%; discontinuation 38% vs 15%, mostly for adverse events.
RCTn = 304
Fernandez et al. Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trial